Cerus Corporation Signs Group Purchasing Agreement with Blood Centers of America
I'm PortAI, I can summarize articles.
Cerus Corporation has signed a group purchasing agreement with Blood Centers of America, covering its INTERCEPT product line, including pathogen reduction technology for platelets, plasma, and the INTERCEPT Fibrinogen Complex. This agreement aims to expand access to these products among BCA's 60+ member blood centers, which produce about half of the U.S. platelet and cryoprecipitate supply. It also includes a resource-sharing model and collaborative training initiatives to promote pathogen reduction technologies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments